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OBJECTIVES This retrospective study was undertaken to provide data on occurrence, significance and
therapy of ventricular tachyarrhythmia (VT) clusters (VTCs) in patients with dilated
cardiomyopathy (DCM) and implantable cardioverter defibrillators (ICDs).
BACKGROUND Data on the clinical significance of VTCs are lacking in patients with DCM and ICDs.
METHODS Baseline characteristics of 106 consecutive patients with DCM and ICDs were prospectively
collected, and chart reviews and episode data retrospectively analyzed. A VTC was defined as
$3 sustained VTs/24 h.
RESULTS During a mean follow-up of 33 6 23 months, 73 patients (68.9%) had recurrent VT or
ventricular fibrillation (VF), 43 patients (40.6%) suffered only single VTs and 30 patients
(28.3%) experienced 52 clusters of VTs. Actuarial survival free of VT or VF was 44.6%, 33.0%
and 26.5%, and survival free of VTC was 77.3%, 72.2% and 67.1% after one, two and three
years, respectively. Independent predictors of VT clusters were heart failure before ICD
implantation (p 5 0.033), presenting monomorphic VT (p 5 0.044), EF ,0.40 (p 5 0.014)
and inducible mVT, especially with right bundle branch block and superior axis configuration
(p , 0.001). Survival free of recurrent VTCs was 50.8%, 38.1% and 19.0% after one, two and
three years, respectively. Once a VTC had occurred, only 56.7%, 46.4%, 30.9% and 15.5% of
patients survived and were not transplanted after one, two, three and four years, respectively.
Survival was even more reduced if a VTC was associated with cardiac decompensation: 65.6%
and 21.9% after one and two years, respectively.
CONCLUSIONS Despite antiarrhythmic intervention, clusters of VTs occur and recur frequently in patients
with DCM. They signify impaired survival, especially if they are associated with cardiac
decompensation, and may be a harbinger of progressive myocardial deterioration rather than
a primarily arrhythmic problem. The benefit of ICD therapy may therefore be low in these
patients. (J Am Coll Cardiol 2000;36:566–73) © 2000 by the American College of
Cardiology
Implantable cardioverter defibrillators (ICDs) have a high
success rate in terminating ventricular tachycardias (VT)
and ventricular fibrillation (VF) (1–3). Some studies, how-
ever, have demonstrated impaired survival in patients with
frequent episodes of ventricular tachyarrhythmias (4–8). In
contrast, one study, mainly on patients with coronary artery
disease (CAD), revealed that these patients did not have a
worse outcome than patients without frequent VTs (9). The
significance of VTCs in patients with dilated cardiomyop-
athy (DCM) could not be determined from these studies
because of the small numbers of patients in each study
population. Furthermore, definitions of clusters varied be-
tween studies, and it remains to be demonstrated which type
of VT or shock cluster is of clinical significance (5–10).
Although frequent episodes are one of the most demand-
ing clinical problems during ICD patients’ follow-up, data
on management of VTCs in patients with ICDs are rare and
inconsistent. Besides, existing data generally refer to few
patients, and only with CAD (7–9,11–13).
Current therapeutic options for incessant and clusters of
VTs are antiarrhythmic medication (11,12,14), radiofre-
quency ablation (15–17), anxiolytic therapy (11) and finally
external cardiopulmonary support and heart transplantation
for intractable incessant VTs (18,19). With the exception of
amiodarone, antiarrhythmic therapy has yielded frustrating
results in patients with VTCs (11,12,14).
The purpose of the present study was to analyze the
incidence, permissive factors and prognostic significance of
VTCs in patients with DCM.
METHODS
Definitions. The assumption that a VT or VF had oc-
curred was based on ICD memory data and clinical infor-
mation. The techniques used to differentiate among VT or
VF, supra-VTs and oversensing have been described previ-
ously (20).
Various definitions of VTCs have been suggested (5–
8,10). For sensitivity, a VTC was defined as at least three
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different sustained episodes of VT or VF terminated by
ICD intervention during 24 h. Repetitive ineffective shocks
were not included.
Patients and baseline examinations. We retrospectively
analyzed data from 106 consecutive patients with DCM
(diffuse left ventricular dysfunction on angiography and
exclusion of CAD and other causes, ejection fraction [EF]
,0.60), who received an ICD, with the capability of
documenting at least four consecutive episodes, at the
University of Mu¨nster (21). All patients underwent an
electrophysiologic study (EPS) off antiarrhythmic drugs or
on amiodarone before ICD implantation. Programmed
ventricular stimulation was performed according to a pro-
tocol presented elsewhere (22).
Variables for risk prediction of VTs, VTCs, shock clus-
ters and final events were prospectively collected in an ICD
database, which included patients’ baseline characteristics
and implantation data (Table 1).
Follow-up. Patients visited the ICD outpatient clinic rou-
tinely every three months and were encouraged to schedule
additional visits if the first shock, a cluster of shocks or
syncope had occurred.
Statistical analysis. Mean 6 standard deviation was used
for continuous variables with normal distribution. In this
case, the t-test was applied to compare means. Median and
range or 95% confidence interval (CI) was used to describe
continuous variables without normal distribution. In this
case, the Mann-Whitney U test was applied. Frequency
distributions between groups of patients were tested by the
chi-square test. A two-tailed p value of #0.05 was regarded
as significant.
The probability of freedom of major events was calculated
according to the Kaplan-Meier method and measured from
the date of implantation, first VT or first VTC to the event
(23). Differences between pairs of actuarial curves were
tested by Mantel-Haenszel log-rank test. Cox regression
analysis was performed on patients’ baseline characteristics
to investigate and compare the influence of different vari-
ables (24). Because the inclusion of drug regimes would
have violated two strong assumptions of the Cox model (the
effects of different variables must be constant over time;
second variables must be independent and additive), drugs
were excluded from the Cox model and variables that
showed interdependence were not used together in the
model. Statistical analysis was done with SPSS (Statistical
Package for Social Sciences, version 6.0) for Windows.
RESULTS
Baseline characteristics. Indications for ICD implantation
were VF in 48 patients (45.3%), polymorphic VT in 3
patients (2.8%), monomorphic VT in 49 patients (46.2%),
nonsustained VT in 4 patients (3.8%) and syncope plus
inducible VT or very low EF in 2 patients (1.9%). Prophy-
lactic indications for ICD implantation were excluded from
analysis (Tables 1 and 2). In 54 patients (50.9%), only
shocks were given and in 52 patients (49.1%), additional
antitachycardia pacing was programmed. The mean detec-
tion cycle length for ICD therapy was 337 6 50 (median
300, range 290–500) ms.
Major events. The mean follow-up was 32.5 6 23 months.
Seventy-three patients (68.9%) had recurrent VTs/VF, 65
patients (61.3%) suffered shocks, 43 patients (40.6%) expe-
rienced single VTs, 30 patients (28.3%) suffered 52 clusters
of VTs and 27 (25.5%) patients had shock clusters. Seven-
teen patients had a single VTC, 13 patients had recurrent
clusters of VTs and 6 had more than 2 recurrent VTCs. A
median of 19 VTs (4 to 440) occurred during clusters. A
median of 4 (0 to 42) VTs were terminated with shocks, 22
clusters of VTs (42.3%) consisted of #3 VTs terminated by
shocks, 30 (57.7%) of .3 VTs terminated by shocks.
Clusters lasted for 2 (1 to 14) days, 24 (46.2%) lasted just 1
day, 28 (53.8%) more than 1 day. Most VTCs consisted of
monomorphic VTs (n 5 45, 86.5%), 31 clusters of VTs
(59.6%) were slower than 200 beats/min, 14 (26.9%) were
faster than 200 beats/min. Four VTCs (7.7%) were poly-
morphic VT or VF clusters and 2 clusters (3.8%) consisted
of VTs with various morphologies.
Twenty-one patients (19.8%) died during follow-up; 12
patients (11.3%) underwent heart transplantation. One was
transplanted immediately after a VTC and died during the
procedure. Sixteen deaths (15.1%) were classified as cardiac,
3 as non-cardiac (2.8%), and the cause of death in 2 patients
(1.8%) remained unknown.
Two patients died of intractable incessant tachycardia and
one from a VT below the detection rate. In two patients
death occurred shortly after two shocks, which terminated
fast VTs promptly. In these patients death was not supposed
to be caused by the tachycardias or by therapy exhaustion.
Thus, in only three patients was death believed to be due to
ventricular arryhthmias. In nine patients no arrhythmia was
documented in the final printout after death. In these cases
death was due to terminal heart failure. Actuarial freedom of
major events is presented in Table 3.
Risk predictors. Patients in NYHA class III (n 5 46),
patients with a history of heart failure before ICD implan-
tation (n 5 40) or with an EF below 0.40 (n 5 69) had a
significantly higher risk of VTC than patients in NYHA
class I (n 5 11) or II (n 5 49, Fig. 1) without a history of
heart failure (n 5 66) or an EF above 0.40 (n 5 66).
Abbreviations and Acronyms
CAD 5 coronary artery disease
DCM 5 dilated cardiomyopathy
EF 5 ejection fraction
EPS 5 electrophysiologic study
ICD 5 implantable cardioverter defibrillator
PVS 5 programmed ventricular stimulation
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
VTC 5 ventricular tachycardia cluster
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Mean EF at baseline was not significantly different
among patients with no VTs (0.38 6 0.12), single VTs
(0.36 6 0.13) and VTCs (0.32 6 0.13), although a
tendency was obvious.
Patients with monomorphic VTs (n 5 53, patients with
monomorphic nsVTs included) presenting with tachycar-
dias had a significantly higher risk of clusters of VTs than
patients who presented with VF or polymorphic VTs (n 5
51): after four years 78.3% of patients with VF or polymor-
phic VTs survived free of a VTC, as opposed to 47.5% of
patients with monomorphic VTs (p , 0.001). Patients in
whom a monomorphic VT could be induced had a signif-
icantly higher risk of a VTC than those in whom no
monomorphic VT or only VF could be induced. Patients in
whom a monomorphic VT with superior axis (left to right
superior), mostly right bundle branch block (RBBB), had a
significantly higher risk of a VTC than those in whom only
monomorphic VTs with inferior axis (left to right inferior)
could be induced (Fig. 2). The inducible VT in patients
with VTCs was slower (311 6 91 ms) than in patients with
singular events (252 6 90 ms, p 5 0.051). No other baseline
variable proved to be predictive of VTCs.
In particular, there was no difference between propor-
tional freedom of VTCs in patients with singular VTs and
more than one VT before ICD implantation, and with sinus
rhythm, atrial fibrillation or a history of atrial flutter.
Cox regression analysis identified prior decompensation,
EF below 0.40 and monomorphic VT as presenting or
Table 1. Baseline Characteristics of Patients
Patients All
Patients With VTs
but Without Clusters
of VTs p Value
Patients With
Clusters of VTs
n 106 43 30
Follow-up (months) 32.5 6 23.0 45.4 6 30.5 20.5 6 13.7
Age (years) 56 6 13 56 6 13 NS 56 6 12
Class of heart failure
NYHA I 10.4% 9.3% 3.3%
NYHA II 46.2% 55.8% 0.017 33.3%
NYHA III 43.4% 34.9% 63.4%
Prior decompensation 37.7% 32.6% NS 50.0%
Ejection fraction 0.26 6 0.13 0.36 6 0.13 NS 0.32 6 0.13
LVED pressure (mmHg) 14.0 6 7.0 14.1 6 6.6 NS 14.2 6 8.2
Echo LVEDD (cm)* 6.6 6 1.0 6.6 6 1.0 NS 6.4 6 0.9
Baseline ECG
Sinus rhythm 49.1% 48.8% NS 46.7%
Atrial fibrillation/flutter† 45.3% 44.2% NS 43.3%
Pacemaker 5.7% 7.0% NS 10.0%
QRS-width (ms)‡ 117 6 35 116 6 36 NS 120 6 32
QT-duration (ms)‡ 402 6 54 397 6 56 NS 413 6 56
Presenting tachyarrhythmia
VF/pVT 48.1% 53.5% — 20.0%
mVT 46.2% 42.9% 0.0233 70.0%
nsVT 3.8% 4.7% NS 3.3%
Syncope 1 inducible VT 1.9% 0% NS 6.7%
Baseline PVS
Inducible VT/VF 53.7% 46.5% 0.0073 66.7%
Inducible mVT 38.7% 30.2% 0.0003 73.3%
RBBB 28.3% 18.6% 0.0019 60.0%
LBBB 8.5% 9.3% NS 10.0%
inferior axis 13.2% 16.3% NS 13.3%
superior axis 24.5% 11.6% , 0.0001 60.0%
Cycle length of induced VT 275 6 91 ms 252 6 90 ms 0.0511 311 6 91 ms
Medication at discharge at first VT first VTC
Class I-AA 3.8% 7.0% NS 3.3%
Beta-blocker 23.6% 23.3% NS 26.7%
Sotalol 10.4% 11.6% NS 6.7%
Amiodarone 12.3% 11.6% NS 16.7%
Ca-antagonist 8.5% 11.6% 0.0530 0%
Digitalis 78.3% 79.1% NS 76.7%
Diuretic medication 69.8% 65.1% NS 80.0%
ACE-inhibitor 76.4% 72.1% NS 76.7%
*Echocardiographic M-mode data available for only 70 patients; †Chronic or intermittent; ‡Patients with pacemakers not included.
AA 5 antiarrhythmic agent; ACE 5 angiotensin converting enzyme; ECG 5 electrocardiogram; LBBB 5 left bundle branch block; LVEDD 5 left ventricular enddiastolic
diameter; mVT 5 monomorphic ventricular tachycardia; NYHA 5 New York Heart Association; nsVT 5 nonsustained ventricular tachycardia; PVS 5 programmed ventricular
stimulation; pVT 5 polymorphic ventricular tachycardia; RBBB 5 right bundle branch block; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia; VTC 5 ventricular
tachycardia cluster.
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inducible VT, especially with RBBB and superior axis, as
independent significant risk predictors of VTCs (Table 3).
NYHA class III could be substituted for a history of heart
failure before implantation and low EF, but did not provide
additional significant information in the Cox model.
Causes of VTCs and intervention. In 18 clusters (34.6%),
no clinical cause could be identified. Sixteen clusters
(30.8%) were associated with heart failure and 18 clusters
with “extrinsic” causes: 10 (19.6%) with diarrhea or low
potassium levels (mean 3.6, range 3.0–4.0 mmol/l on the
day of the VT cluster), 2 with fever and 2 with strain
(operation/traveling). Two clusters were attributed to proar-
rhythmia (QT-time prolongation associated with antiar-
rhythmic medication): one—a polimorphic VT cluster—
was associated with hyperkalemia (potassium level of
7.9 mmol/l), and one was assumed to be due to discontin-
uation of antiarrhythmic therapy.
The risk of a recurrent VTC was high: only 50.8%, 38.1%
and 19% of patients survived free of a recurrent VTC after
one, two and three years, respectively (Table 2). Survival
free of a recurrent shock cluster was 58.0%, 37.3% and
37.3% after one, two and three years, respectively. The
recurrence risk of shock clusters tended to increase with
number of VTs documented during the first VTC (3 to
6 VTs: 28.6%, 7 to 12 VTs: 35.7%, 13 to 24 VTs: 33.3%,
.24 VTs: 57.9%, p 5 0.074) and the duration of the first
VTC (1 day: 31.6%, .1 day: 65.2%, p 5 0.030).
The risk of a recurrence was not related to the first cluster
being a shock cluster or a cluster with antitachycardia
pacing, although physicians more often decided in favor of
an antiarrhythmic therapy if a VTC was a shock cluster.
Antiarrhythmic intervention performed after 24 VTCs did
not show any impact on VTC recurrence: the proportion
free of recurrent VTCs was 75%, 59.6%, and 47.7% after
intervention and 78.4%, 50.1%, and 37.8% without inter-
vention after one, two, and three years, respectively (N.S.).
Sixteen clusters (30.8%) occurred while patients were on
beta-blockers. Survival free of shock clusters was 90.0%,
82.1%, 75.8% and 60.7% if patients were discharged on a
beta-blocker after one, two, three and four years, respec-
tively (n 5 25).
Six VTCs occurred while patients were on sotalol and 16
while patients were taking amiodarone and 3 with patients
taking amiodarone and a beta-blocker. The risk of a
recurrent VTC was 40% on sotalol and 57.1% on amioda-
rone, and one cluster recurred on amiodarone and a beta-
blocker. Projected survival free of VTCs after prescription of
a class III antiarrhythmic was 72.9%, 62.5% and 31.3% after
one, two and three years, respectively.
Patients on beta-blockers seemed to fare better than
patients on class III antiarrhythmic drugs as far as risk of
clusters was concerned. This may only be because patients
discharged on beta-blockers were better as far as LV
function and frequency of tachycardias before ICD implan-
tation was concerned. Because of this bias, the “effect” of
antiarrhythmic drugs should be viewed with caution.
A class I antiarrhythmic drug was initiated after VTCs in
Table 2. Kaplan-Meier Analysis for Major Events
Survival Free of (%)
1st
Year
2nd
Year
3rd
Year
4th
Year
VT/VF 44.6 33.0 26.5 24.6
Shocks 52.8 39.6 30.9 29.0
VTC 77.3 72.2 67.1 64.8
Shock cluster 80.2 76.3 73.0 68.5
Recurrent VTC (n 5 30) 50.8 38.1 19.0 19.0
Recurrent shock cluster
(n 5 27)
58.0 37.3 37.3 37.3
Death 92.1 81.4 78.1 73.9
Cardiac death 93.9 85.9 82.4 80.2
Sudden death 97.1 89.8 89.8 87.5
Heart transplantation 93.9 89.8 87.9 85.5
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia; VTC 5 ventricular
tachycardia cluster.
Table 3. Cox Regression Analysis for Major Events
Dependent variable predictor b Odds Ratio p Value
VTC
Prior decompensation 10.41 1.51 (1.04–2.21) , 0.033
EF ,0.40 10.69 1.98 (1.15–3.43) , 0.015
Presenting mVT 10.44 1.55 (1.01–2.38) , 0.045
Inducible mVT with superior axis 11.03 2.80 (1.66–4.71) , 0.001
All-cause mortality 1 heart transplantation
Prior decompensation 10.82 2.27 (1.55–3.33) , 0.001
Inducible mVT 10.57 1.77 (1.22–2.55) , 0.003
VTC* 10.75 2.12 (1.46–3.09) , 0.001
All-cause mortality
Prior decompensation 10.68 1.97 (1.11–3.49) , 0.021
Inducible mVT 10.56 1.75 (1.08–3.49) , 0.022
VTC* 10.77 2.17 (1.35–3.48) , 0.002
Sudden death
NYHA I 1 II 21.14 0.32 (0.11–0.94) , 0.026
VTC 10.83 2.30 (1.11–4.77) , 0.038
*If clusters of VTs are substituted for inducible mVT. MVTs and VTCs could not be analyzed together, because this would have
violated the assumption of the Cox regression model that factors have to be independent.
mVT 5 monomorphic ventricular tachycardia; NYHA 5 New York Heart Association; VTs 5 ventricular tachycardia;
VTC 5 ventricular tachycardia cluster.
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three patients. All three had a recurrence; one patient died
during a VTC. In six patients a beta-blocker was given after
a VTC; one VTC recurred (16.7%). This may suggest a
benefit of beta-blockers in these circumstances in line with
the favorable outcome of patients discharged on beta-
blockers.
Sotalol was given empirically in five patients, three had a
recurrent VTC. Amiodarone was prescribed in seven pa-
tients, of whom two had a recurrence. Amiodarone and a
beta-blocker were prescribed in one patient after a VTC; he
had a recurrent VTC. Amiodarone was added to the
medication after shock clusters in all cases: only one patient
had a recurrent shock cluster during a mean follow-up of
29.4 months. In patients in whom the cluster recurred,
number of VTs (19, 5-157 before intervention and 31, 4-64
after) and number of shocks (3, 0-23 before intervention
and 12, 0-42 after) were increased, mainly in patients on
sotalol. The duration of clusters was reduced (2, 1-7 vs. 1,
1-2; p 5 0.076).
As stated in the method section, drugs at discharge were
not included in the Cox model because they violated the
assumption of continuity.
In two patients radiofrequency catheter ablation was
performed. Both had a recurrence of a VTC. Only 2 of 30
patients with VTCs were listed for heart transplantation.
They had no recurrent VTC. Two patients died during or
shortly after VTCs. In two patients, other measures (seda-
tion, etc.) were taken. In all 16 patients in whom VTCs
were associated with heart failure, therapy was intensified
and 5 had a recurrent VTC; 1 died during a VTC. In three
patients, prescription of an angiotensin-converting enzyme
inhibitor was the only therapeutic move; one had a recurrent
VTC. In 12 patients, potassium was added to the medica-
tion. In 6 patients this was the only change in therapy; 6 had
a recurrent VTC.
Clinical significance. Among all VTCs, 78.4% led to
hospitalization, which was significantly associated with the
number of VTs and shocks: clusters with #3 shocks led to
hospital admission in 50% of cases, whereas those with .3
shocks led to hospitalization in all cases (p 5 0.006).
Clusters with up to 6 VTs (n 5 7) caused hospital
admission in 42.9% of cases, whereas more than 6 VTs
during one cluster (n 5 45) led to hospitalization in 84.4%
of cases. All clusters associated with heart failure (n 5 16),
88.9% associated with extrinsic causes (n 5 18), and only
50% of clusters with no definable cause resulted in hospi-
talization (p , 0.001).
Irrespective of the number of VTs during a cluster,
survival in patients with clusters of VTs was significantly
impaired in comparison with patients who had only single
VTs or no VTs (Fig. 3). Among patients with single VTs,
85.4% survived four years after implantation, in contrast to
45.8% of those clusters of VTs (p , 0.004). Only 26% of
patients with VTCs survived four years after ICD implan-
tation and were not transplanted, compared with 78.2% of
patients with single VTs (Fig. 3, p , 0.001). A total of
56.7%, 46.4%, 30.9% and 15.5% of patients survived with-
out transplantation one, two, three and four years after first
VTC. There was no significant difference in survival or
survival free of heart transplantation after clusters of VTs
with few or many VTs or shocks (two-year survival after 3 to
6 VTs was 42.9%, 6 to 12 VTs was 45%, and after .12 VTs
50%). If VTCs were associated with heart failure, survival
was significantly reduced (65.6% and 21.9% after one and
two years, respectively) compared with clusters of VTs
associated with extrinsic causes (hypokalemia, diarrhea etc.,
86.9% and 69.5% after one and two years, respectively, p 5
0.0467)) or no cause (88.9% and 73.3%, after one and two
years, respectively, p 5 0.0450).
Figure 1. Cluster-free survival in different NYHA-classes at baseline.
NYHA 5 New York Heart Association.
Figure 2. Cluster-free survival and inducible VT during baseline pro-
grammed ventricular stimulation. Patients in whom no VT could be
induced and patients in whom VF or polymorphic VTs were induced were
taken together in the no-monomorphic-VT group, because they did not
differ significantly in cluster-free survival. Superior axis describes VTs with
left-to-right superior axis, inferior axis describes VTs with left-to-right
inferior axis.
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DISCUSSION
Definitions and clinical significance of VTCs. This study
is the largest study on VTs and the first on VTCs in patients
with DCM. In order to be sensitive, we used the very low
inclusion definition of 3 VTs or more during 24 h from
Hariman et al. (25), also used by Credner et al. (9). With
this definition, almost 80% of clusters led to a hospitaliza-
tion and were clinically significant. Most clusters actually
consisted of many VTs, with the median being 19 (range 4
to 440), and only 13.5% of clusters consisted of ,6 VTs.
The probability of hospitalization because of clusters was
associated with the number of VTs, the number of shocks
during one cluster and concurrent heart failure.
The occurrence of clusters predicted impaired survival in
patients with DCM. Irrespective of the number of VTs,
only 30.2% of patients survived and 15.5% survived without
heart transplantation four years after the first cluster. Sur-
vival was significantly worse in patients in whom VTCs
were associated with cardiac decompensation, as opposed to
patients in whom an extrinsic cause or no cause of the VTC
could be identified.
This result is in line with those of other studies. Wood et
al. (4) found an association between the frequency of
delivered therapies and shocks with total and cardiac mor-
tality in a cohort of 401 patients, of whom 49 (12.4%) had
DCM. However, frequent terminal shocks could not be
excluded as a cause of this association, and details about
patients and frequent episodes were not available (4). We
found no significant association between frequency of
shocks during clusters of VTs and survival. The study of
Villacastin et al. (7) also revealed an increased death rate
after multiple consecutive discharges: 7 of 25 patients (28%)
with nonischemic cardiomyopathy and VT clustering died
during follow-up, in contrast to 4 of 47 (8.5%) with previous
myocardial infarction. However, clusters were defined as
two or more discharges that occurred only a few seconds
apart or were considered part of a single arrhythmic episode.
This definition of VT clustering may in some cases repre-
sent an increase in defibrillation threshold or incessant VTs,
rather than frequent recurrences of VTs. In a study by Fries
et al. (8), total mortality and cardiac mortality was 24% to
29% in the group with and 4% in the group without
short-term recurrent tachyarrhythmias (9). In their study 34
patients with clusters were presented; only 9 of these
patients had a DCM and neither a survival analysis nor a
comparison between different types of VTCs was presented.
The relation among heart failure, mortality and VTCs
or inducible VTs requires explanation. On the one hand, it
has been suggested that frequent VTs, and especially inces-
sant VTs may cause congestive heart failure (26). Further-
more, animal (27) and echocardiographic studies (28–30)
have suggested that left ventricular function, especially
diastolic function and survival, may be impaired by
shocks. This finding is in line with the fact that VTCs
were often associated with heart failure and that heart
failure was reversible in all but two cases. On the other
hand, progressive scarring of the left ventricular free wall
may increase susceptibility to re-entrant tachycardias
(16,31–33). Therefore, clusters of VTs may be an additional
powerful marker, rather than the cause, of cardiac deterio-
ration in patients with DCM. This is supported by the fact
that inducible VTs, VTCs and heart failure (NYHA) before
ICD implantation were the only predictors of all-cause
mortality, heart transplantation and sudden death (Table 3).
Risk prediction of VTCs. In our study, NYHA III heart
failure before ICD implantation, low EF monomorphic VT
as index tachycardia and the inducibility of a monomorphic
VT, especially with superior axis, were the best predictors of
an increased risk of VTCs in patients with DCM (Tables 2
and 3). One other study in 82 patients with ICDs, in whom
16 had VTCs, also found a significant difference in func-
tional status and left ventricular function between patients
with single episodes of VTs and patients with multiple
consecutive discharges during a follow-up of 21 6 19
months (7). In 9 of 16 patients with multiple discharges,
functional class deteriorated during follow-up, which is in
accordance with our finding that 30.8% of VTCs were
associated with heart failure.
A predictive value of the presenting arrhythmia or the
PVS for major events in patients with DCM has not yet
been demonstrated, and the prognostic value of PVS in
patients with DCM has been drawn into question (3,29,30).
In our study, however, frequent recurrences of VTs could be
anticipated with the results of PVS.
Intervention. The risk of a recurrent VTC was high,
irrespective of antiarrhythmic intervention. Only 19% of
patients remained free of a second VTC after three years.
The risk of recurrences was associated with the number of
VTs during a VTC and the duration and cause of a VT
cluster. Interestingly, the recurrence risk of VTCs was
Figure 3. Survival free of heart transplantation in patients with single or no
VTs and VTCs after implantation. VT 5 ventricular tachycardias; VTC 5
ventricular tachycardia cluster.
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highest in patients in whom hypokalemia and associated
conditions such as diarrhea and vomiting were noted (50%)
or in patients in whom no clinical cause (52.9%) could be
identified, and lowest in patients in whom VTCs were
associated with cardiac decompensation (27%). This finding
may be due to shorter follow-up because of high mortality in
the latter group, but it also implies that patients with VTCs
associated with extrinsic causes can hardly be secured
against a recurrence by avoiding permissive factors.
The recurrence rate after antiarrhythmic intervention was
only slightly and not significantly better than after no
intervention: only 38% of clusters did not recur without
intervention, as opposed to 48% with intervention. The risk
of a recurrent VTC was only slightly lower if the antiar-
rhythmic medication was changed as opposed to maintained
(47%) or escalated with a second antiarrhythmic (38%).
This slight improvement was attributable to patients in
whom amiodarone or a beta-blocker were prescribed after a
VTC (9,13). This is in line with the findings on patients
with CAD and VTCs reported by Credner et al. (9,34). The
small benefit of antiarrhythmic therapy in patients with
clusters of VTs is in line with a study from Dijkman, which
reported that in seven of nine patients with postoperative
VT storm, an average of 3.8 antiarrhythmic drugs were
tried: only two patients could be stabilized with a combi-
nation of two drugs alone, three patients could be handled
with overdrive stimulation, and four had to be sedated (11).
Similarly, Kou et al. (14) showed that antiarrhythmic
intervention offered no benefit after a single episode of VT
in patients with ICD, but seemed to increase the risk of
syncope during VTs. Antiarrhythmic drugs given on clinical
grounds, i.e., without electrophysiologic testing, were no
better in reducing the risk of recurrent tachycardias than no
antiarrhythmic drugs (14). One reason may be that drugs
that slow conduction may render the patient more suscep-
tible to re-entrant tachycardias.
Study limitations. A retrospective analysis of complex
events such as clustering of VTs is difficult from different
points of view: inadequate episodes may be erroneously
taken for clusters of VTs. Our analysis revealed that there
was no difference between survival free of VTCs in patients
with sinus rhythm and in patients with atrial fibrillation and
flutter. Because atrial fibrillation is one of the strongest
predictors and causes of inadequate episodes, we assume
that differentiation of VTCs from other kinds of episode
clustering was sufficiently achieved (35).
The differences of recurrent VTCs after interventions
have to be viewed with caution, because there was no
uniformity between interventions, and intervention de-
pended on the treating physician’s preference.
The finding that VTCs are associated with impaired
survival is an important observation. However, therapeutic
conclusions should be drawn with caution as long as
prospective confirmation is lacking.
CONCLUSIONS
Clusters of VTs occur frequently in ICD patients with
DCM. Major predictors of VTCs were prior decompensa-
tion, EF below 0.40, and presenting or inducible monomor-
phic VT, especially with RBBB and superior axis configu-
ration. In patients with DCM even clusters of as few as
3 VTs during 24 h anticipated impaired survival, as opposed
to singular events, especially if they were associated with
heart failure. Clusters of VTs together with monomorphic
VTs, either as index or inducible tachycardia, may rather be
seen as a useful additional criterion for the evaluation of a
patient for a heart transplantation than as a primarily
arrhythmic problem. Use of VT clustering as an additional
criterion for listing should be prospectively tested.
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